How To Make More Periodontal Therapeutics Market By Doing Less

Rising prevalence of periodontal diseases

The growing prevalence of periodontal diseases such as periodontitis and gingivitis is the primary factor driving the growth of the periodontal therapeutics market globally. Periodontitis is considered one of the major oral diseases considering the rate of infection among the population and its overall effect on the overall health

According to WHO, approximately 10% of the global population is affected by severe periodontal (gum) disease by 2020. The prevalence of gum diseases is significant in the U.S. and Europe. Gum disease is reported in nearly 40% of Europeans aged 65 to 74 and 5-20% of the middle-aged population in the region

The prevalence of gum diseases is likely to increase with a growing population prone to stress and an increasing diabetic population. An aging population, unhealthy eating habits, and oral hygiene are some other factors that may result in the growth of periodontal therapeutics

Also, the treatment for gum disease is witnessing a rapid shift from surgery towards medicine owing to improved diagnostics and disease classification, advancements in therapeutics for removing microbial periodontal infection, and clinical results of antibiotics' role in the treatment

The non-surgical treatment procedures for gum disease include the use of antibacterial products and deep cleaning of the mouth which are proven to be sufficient for reversing the periodontal disease in its early stages. Adjuvant therapies following the use of antibiotics will support the trend. Antibiotics including both topical and oral are prescribed to control inflammation and plaque of the gum tissue. Oral antibiotics are placed in the gaps formed between gums and teeth by microbial infection, commonly called periodontal pockets

Development of herbal drugs for periodontitis

The ongoing research for use of herbal medicine in the treatment of periodontitis is likely to provide new growth avenues for the periodontal therapeutics market

Several botanical drugs reportedly with antimicrobial, anti-inflammatory, and anti-collagenase properties are under consideration for use in treating periodontitis

AngioLab’s AL201-AB is a botanical drug that inhibits tooth loss by inhibiting MMP-1, -8, -9, and -13. It is under phase-2 clinical trials in 2020 as a periodontal therapeutic

Herbal extracts from green tea, Triphala, Sumac, and Gingko Biloba are clinically proven to play a role in oral diseases. These are already in use as ingredients in oral hygiene products owing to this capacity

These herbal medicines are likely to evolve as an adjunct in periodontal therapies, thus widening the market scope

Trials of vaccine for oral diseases

Besides antibiotics, the periodontal vaccine is the next range of therapeutics proposed in periodontology

Vaccination is the most effective application method of immunological principles to human health. Thus, the large prevalence rate of periodontitis is motivating the development of a vaccine

Researchers in the U.S. have developed a conjugate vaccine based on purified capsular polysaccharide of Porphyromonas gingivalis in 2021

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com